Gemer Sita IR 50/1000/1 Tablet is a combination oral antihyperglycemic medication containing Sitagliptin 50 mg, Metformin 1000 mg, and Glimepiride 1 mg, indicated for the management of type 2 diabetes mellitus. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the incretin system by increasing levels of active incretin hormones, which improve glucose-dependent insulin secretion and decrease glucagon release, thereby aiding in glycemic control. Metformin, a biguanide, primarily reduces hepatic glucose production and improves peripheral insulin sensitivity, contributing to lower blood glucose levels. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to release insulin, further assisting in the regulation of blood glucose. This fixed-dose combination is designed for patients inadequately controlled on monotherapy or dual therapy, providing complementary mechanisms to achieve optimal glycemic control. Gemer Sita IR should be administered with meals to minimize gastrointestinal side effects associated with Metformin. Caution is advised in patients with renal or hepatic impairment, and regular monitoring of blood glucose and renal function is recommended. Potential adverse effects include hypoglycemia, gastrointestinal disturbances, and rare hypersensitivity reactions. This medication should be used under strict medical supervision as part of a comprehensive diabetes management plan including diet and exercise.